In vivo characterization of inhibitory anti-PD-1 antibody superagonists

被引：0
|
作者：
Akkaya, B. [1 ,2 ]
Davis, S. J. [1 ,2 ]
Cornall, R. J. [1 ,2 ]
机构：
[1] Univ Oxford, Nuffield Dept Clin Med, Oxford, England
[2] Univ Oxford, MRC Human Immunol Unit, Oxford, England
来源：
IMMUNOLOGY | 2011年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [41] HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
    Booth, Laurence
    Roberts, Jane L.
    Poklepovic, Andrew
    Avogadri-Connors, Francesca
    Cutler, Richard E.
    Lalani, Alshad S.
    Dent, Paul
    ONCOTARGET, 2017, 8 (52): : 90262 - 90277
  • [42] Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody
    Satoshi Iyama
    K. Takada
    M. Yoshida
    D. Takahashi
    M. Kobune
    Annals of Hematology, 2020, 99 : 1669 - 1670
  • [43] Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab)
    Kaini Shen
    Yuehua Liu
    Xinxin Cao
    Daobin Zhou
    Jian Li
    Annals of Hematology, 2017, 96 : 687 - 688
  • [44] Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models
    Kumar, Sujatha
    Ghosh, Srimoyee
    Sharma, Geeta
    Wang, Zebin
    Kehry, Marilyn R.
    Marino, Margaret H.
    Neben, Tamlyn Y.
    Lu, Sharon
    Luo, Shouqi
    Roberts, Simon
    Ramaswamy, Sridhar
    Danaee, Hadi
    Jenkins, David
    MABS, 2021, 13 (01)
  • [45] Model-based Characterization of the Clinical Pharmacokinetics of Nivolumab, a Fully Human Anti-PD-1 Monoclonal Antibody
    Feng, Yan
    Agrawal, Shruti
    Kollia, Georgia
    Saeger, Sally
    Ullmann, Martin
    Sankar, Vindira
    McDonald, Dan
    Gupta, Ashok
    Masson, Eric
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S141 - S142
  • [46] Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti-PD-1 antibody
    Iyama, Satoshi
    Takada, K.
    Yoshida, M.
    Takahashi, D.
    Kobune, M.
    ANNALS OF HEMATOLOGY, 2020, 99 (07) : 1669 - 1670
  • [47] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [48] POPULATION PHARMACOKINETICS OF AN ANTI-PD-1 ANTIBODY, PENPULIMAB IN PATIENTS WITH ADVANCED MALIGNANCIES
    Chen, Benchao
    Jin, Xiaoping
    Dong, Yongcheng
    Wang, Max
    Xia, Dennis
    Xia, Michelle
    Li, Baiyong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A471 - A471
  • [49] C3 glomerulonephritis in a patient treated with anti-PD-1 antibody
    Ville, Simon
    Kandel-Aznar, Christine
    Fremeaux-Bacchi, Veronique
    Fakhouri, Fadi
    EUROPEAN JOURNAL OF CANCER, 2020, 125 : 46 - 48
  • [50] Subacute cutaneous lupus erythematosus associated with anti-PD-1 antibody Cemiplimab
    Fietz, S.
    Froehlich, A.
    Sirokay, J.
    Wenzel, J.
    de Vos, L.
    Fetter, T.
    Jansen, P.
    Landsberg, J.
    Hoffmann, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 69 - 69
12345